New type of molecular switch could turn up the volume on bowel cancer treatment

November 5, 2012, University of Dundee

(Medical Xpress)—A new type of molecular switch can boost common chemotherapy drugs to destroy bowel cancer cells, according to research presented today (Monday) at the NCRI Cancer Conference in Liverpool.

Scientists at the University of Dundee examined hundreds of molecules which may help to predict whether bowel can be successfully treated with chemotherapy.

Many bowel cancer patients are treated with a drug called 5-fluorouracil, or 5-FU, but not all patients respond well. It is difficult to predict which patients will be successfully treated.

The team revealed in laboratory experiments that blocking a called miR-224 'tricks' bowel cancer cells containing a healthy gene called K-RAS into behaving like cells with a damaged form of the gene.

K-RAS usually controls the normal growth of healthy bowel cells. But faulty versions of K-RAS are found in one third of bowel cancers, particularly in fast-growing cancers with poor survival.

The research showed that common drugs, 5-FU and , were more effective in treating bowel cancer cells with damaged forms of K-RAS, and bowel cancer cells with healthy K-RAS in which the miR-224 switch had been blocked.

Lead author, Dr Gillian Smith, at the University of Dundee, said: "Our research reveals that changing the behaviour of K-RAS boosts the effect of certain drugs to kill bowel .

"This research is at an early stage, but if we're able to prove these results in larger studies, the findings could provide new scope for bowel cancer treatments targeting the K-RAS gene. Our findings are particularly interesting because there is already a test available in the clinic that can identify which patients have a faulty version of K-RAS."

Bowel cancer is one of the most commonly diagnosed cancers in the UK with more than 41,000 people diagnosed with the disease in the UK each year.

Dr Jane Cope, director of the NCRI, said: "This is exciting research that adds to the dramatic progress made over the past thirty years in tackling .

"People diagnosed today are twice as likely to survive for at least ten years as those diagnosed in the 1970s and we hope that these findings will one day help scientists develop better ways to treat and monitor the disease in the future - ultimately increasing survival from cancer."

Explore further: Bowel screening helps to detect early cancers before they become deadly, study finds

Related Stories

Bowel screening helps to detect early cancers before they become deadly, study finds

November 5, 2012
(Medical Xpress)—Bowel screening is detecting more cancers when they are less mature and have less aggressive biological characteristics according to new research presented at the NCRI Cancer Conference in Liverpool this ...

Scientists discover how iron levels and a faulty gene cause bowel cancer

August 9, 2012
High levels of iron could raise the risk of bowel cancer by switching on a key pathway in people with faults in a critical anti-cancer gene, according to a study published in Cell Reports today.

Screening helps early diagnosis of bowel cancer

June 18, 2012
(Medical Xpress) -- Patients who attend bowel screening are more likely to be diagnosed with bowel cancer at an early stage - when there is a better chance of survival - than those who wait until they have symptoms of the ...

Poor men more likely to die from bowel cancer

November 7, 2011
(Medical Xpress) -- Deprived men are more likely to die from bowel cancer than men from the most affluent section of society, new research presented at the NCRI Cancer Conference in Liverpool this week shows.

Bowel screening reduces cancer deaths by more than 25 per cent

November 9, 2011
(Medical Xpress) -- Bowel screening reduces the number of deaths from bowel cancer in Scotland by more than 25 per cent, according to research* presented at the National Cancer Research Institute (NCRI) Cancer Conference ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.